Skip to main content

Graduate

All trials

Alzheimer

Graduate

Leeftijd icoon
50 - 90 years (M / F)
Diagnose icoon
Diagnosis mild cognitive impairment (MCI), light stage Alzheimer's disease
Duratie onderzoek
2 years
Locatie icoon
Amsterdam

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently.

Phase III, multicenter, randomized, double-blind, placebo-controlled study. The target population for this study is men and women between the ages of 50 and 90, diagnosed with mild cognitive impairment due to Alzheimer’s disease (MCI) or mild-stage Alzheimer’s disease.

The research drug Gantenerumab is a new drug against Alzheimer’s disease. With this study, the researchers want to find out more about the safety and effectiveness of the drug. You will visit our research center about twice a month in two years. The study is divided into three stages, with the option to participate in a follow-up study. You will receive an injection of Gantenerumab or placebo approximately every two weeks for two years. Half of the participants will receive the drug and the other half a placebo. During a few visits, questionnaires will be taken, blood tests and physical examinations will take place and MRI scans will be made. During this phase, there is the option that some visits can be made at home and performed by a home nurse.

This study is commissioned by Roche.

This text has been directly translated from the Dutch trial description as approved by the Ethical Committee.

Screening and selection

During three visits in a maximum period of twelve weeks, it is determined whether you meet the research criteria and whether your health allows participation in the study. If so, you may participate in the study. The selection includes blood tests, physical examinations, memory tests, questionnaires, an MRI scan, and a spinal tap.

Optional extension

After the study, you can participate in an extension of the study. During this phase, each participant will receive an IV of Gantenerumab and there is no placebo group.

Who can participate?

  • You have a diagnosis of Mild Cognitive Impairment (MCI) or mild-stage Alzheimer’s disease
  • You are between 50-90 years old
  • Use of Alzheimer’s medication is permitted, provided it has been the same dose for more than three months.
  • You have a family carer who can accompany you during a few visits to the research center and answer questions about your health and functioning, among other things.

Take action against Alzheimer’s. Sign up to participate.

Latest Dementia trials

Filter

All trialsAlzheimer

Alnylam

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALN-APP is for the treatment of participants with MCI or mild dementia due to early onset Alzheimer’s disease, where the disease began before the participant was 65 years old. The study compares the effect of the new drug ALN-APP with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through an injection into the fluid surrounding the spinal cord.

audience18+

levelAlzheimer’s or mild dementia due to early onset Alzheimer’s disease

duration152 weeks

locationAmsterdam

All trialsAlzheimer

REMAD 02

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer's disease

duration9 weeks

locationAmsterdam

All trialsAlzheimer

APOLLOE4

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.

audience50 - 80 years

level Early-stage Alzheimer’s disease and ApoE4/4 genotype

duration93 weeks

locationAmsterdam, Den Bosch, and Zwolle